Codex DNA, Inc. (NASDAQ: DNAY) announced that it released its first full-length synthetic genome for the highly infectious Delta variant of the SARS-CoV-2 virus (B.1.617 lineage).
The latest genome for the Delta variant was sequenced using the company’s BioXp 3250 system, a fully automated synthetic biology benchtop workstation for rapid, accurate and reproducible writing of DNA and mRNA.
“Emerging SARS-CoV-2 variants continue to wreak havoc around the world. Codex DNA is committed to building and providing innovative synthetic tools that accelerate virus research and simplify the discovery and development processes,” said Todd R. Nelson, Ph.D., CEO of Codex DNA. “We believe this new synthetic genome will be a key resource to identify, monitor, and combat the SARS-CoV-2 virus in our ongoing fight against COVID-19.”
The San Diego-based company was founded in 2011 and entered the public market in June of this year after closing an IPO that raised approximately $122.7 million in gross proceeds before underwriting discounts, commissions and other expenses.
The Codex DNA technology offers researchers an automated technology for rapid drug discovery and genome sequencing. The company currently offers a catalog of 13 SARS-CoV-2 synthetic genomes as well as custom-made SARS-CoV-2 genomes that are used for developing or testing monoclonal antibody treatments, small-molecule therapies, or new vaccines against specific variants.
